|
Keywords
|
خون, لکوسیت, مونوسیت, شیمی درمانى, دوکسوروبیسین, آپوپتوز
|
|
Abstract
|
Chemotherapy is a well-known and effective treatment for different cancers. Chemotherapy drugs can
activate multiple signaling pathways and augment the secretion of inflammatory mediators.
Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in
clinical use.Emerging evidence points to the pleiotropic anticancer activity of DOX. Its cytotoxic
effect produced by intercalating with DNA causing breakdown of DNA strand which causes cancer
cell apoptosis. Has significant effects on blood cells. It primarily targets cancer cells by interfering
with DNA replication, but it also impacts healthy blood cells. One of the notable side effects of
doxorubicin is its contribution to chemotherapy-induced anemia. This occurs because doxorubicin can
damage red blood cells (RBCs) during infusion, as well as suppress bone marrow function, which
reduces the production of new RBCs. Doxorubicin also affects white blood cells (WBCs), leading to
immune suppression. It can decrease the number of circulating WBCs, particularly neutrophils, a
condition known as neutropenia. This makes patients more susceptible to infections, as their immune
system is weakened.
|